Virica Biotech and FUJIFILM Biosciences Partner to Scalably Boost Viral Vector Yields for Gene Therapies
Virica Biotech and FUJIFILM Biosciences collaborate to optimize AAV production using Viral Sensitizer technology and BalanCD HEK293 media for gene therapies.
By: AXL Media
Published: Apr 9, 2026, 4:05 AM EDT
Source: Information for this report was sourced from Virica Biotech and FUJIFILM Biosciences
HEADLINE
Virica Biotech and FUJIFILM Biosciences Partner to Scalably Boost Viral Vector Yields for Gene Therapies
SUMMARY
Virica Biotech has entered a strategic collaboration with FUJIFILM Biosciences to optimize viral sensitizer formulations for Adeno-Associated Virus (AAV) production using the BalanCD HEK293 media system. Supported by funding from the National Research Council of Canada, the partnership aims to address critical manufacturing bottlenecks by delivering an off-the-shelf solution designed to increase AAV productivity and reduce costs for global therapeutic developers.
CONTENT
Bridging the Productivity Gap in Viral Vector Manufacturing
Categories
Topics
Related Coverage
- Whitehead Institute Researchers Re-engineer Human Producer Cells to Enhance Potency of Gene Editing Delivery Vehicles
- Critical Path Institute Launches One to Millions Initiative to Standardize and Scale Individualized Genetic Therapies for Rare Diseases
- Critical Path Institute Launches Global One to Millions Initiative to Scale Individualized Medicine via Modular Regulatory Frameworks
- Insilico Medicine Receives IND Clearance for First AI Developed Inhalation Treatment Entering Direct to Lung Clinical Trials